| |  Online-Ressource |
|---|
| Verfasst von: | Hirjak, Dusan [VerfasserIn]  |
|---|
| | Rogers, Jonathan P. [VerfasserIn] |
|---|
| | Wolf, Robert Christian [VerfasserIn] |
|---|
| | Kubera, Katharina Maria [VerfasserIn] |
|---|
| | Fritze, Stefan [VerfasserIn] |
|---|
| | Wilson, Jo Ellen [VerfasserIn] |
|---|
| | Sambataro, Fabio [VerfasserIn] |
|---|
| | Fricchione, Gregory [VerfasserIn] |
|---|
| | Meyer-Lindenberg, Andreas [VerfasserIn] |
|---|
| | Ungvari, Gabor S. [VerfasserIn] |
|---|
| | Northoff, Georg [VerfasserIn] |
|---|
| Titel: | Catatonia |
|---|
| Verf.angabe: | Dusan Hirjak, Jonathan P. Rogers, Robert Christian Wolf, Katharina Maria Kubera, Stefan Fritze, Jo Ellen Wilson, Fabio Sambataro, Gregory Fricchione, Andreas Meyer-Lindenberg, Gabor S. Ungvari & Georg Northoff |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 18 July 2024 |
|---|
| Umfang: | 18 S. |
|---|
| Fussnoten: | Gesehen am 27.02.2025 |
|---|
| Titel Quelle: | Enthalten in: Nature reviews. Disease Primers |
|---|
| Ort Quelle: | Basingstoke : Nature Publishing Group, 2015 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 10(2024), 1, Seite 1-18 |
|---|
| ISSN Quelle: | 2056-676X |
|---|
| Abstract: | Catatonia is a neuropsychiatric disorder characterized by motor, affective and cognitive-behavioural signs, which lasts from hours to days. Intensive research over the past two decades has led to catatonia being recognized as an independent diagnosis in the International Classification of Diseases, 11th Revision (ICD-11) since 2022. Catatonia is found in 5-18% of inpatients on psychiatric units and 3.3% of inpatients on medical units. However, in an unknown number of patients, catatonia remains unrecognized and these patients are at risk of life-threatening complications. Hence, recognizing the symptoms of catatonia early is crucial to initiate appropriate treatment to achieve a favourable outcome. Benzodiazepines such as lorazepam and diazepam, electroconvulsive therapy, and N-methyl-d-aspartate antagonists such as amantadine and memantine, are the cornerstones of catatonia therapy. In addition, dopamine-modulating second-generation antipsychotics (for example, clozapine and aripiprazole) are effective in some patient populations. Early and appropriate treatment combined with new screening assessments has the potential to reduce the high morbidity and mortality associated with catatonia in psychiatric and non-psychiatric settings. |
|---|
| DOI: | doi:10.1038/s41572-024-00534-w |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1038/s41572-024-00534-w |
|---|
| | Volltext: https://www.nature.com/articles/s41572-024-00534-w |
|---|
| | DOI: https://doi.org/10.1038/s41572-024-00534-w |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Diagnostic markers |
|---|
| | Neural circuits |
|---|
| K10plus-PPN: | 1918683735 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
